Stay updated with breaking news from Partial Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint at first response assessment.
Real-World Results Demonstrate Objective Response Rate of 67% in 24 EBV+ PTLD Patients 91% Overall Survival at One Year for Patients Responding to Tab-cel Compared to 34% for... | June 5, 2023
Hisashi Kobayashi, whose steady leadership as dean guided Princeton's School of Engineering and Applied Science through a rapid expansion of programs and facilities in the late 1980s and early 1990s, died on March 9. He was 84.
Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.